Position in ENTA
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$396,619
-$58,329 QoQ
Shares Held
31,403
+8.9% QoQ
Ownership
0.108%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority
Sole 16%
Shared 0%
None 84%
Common Shares in ENTA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026RHUMBLINE ADVISERS holds $1,238,289,073 across 287 Biotechnology names. ENTA ranks #172 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
423,140 | $188,948,935 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
157,781 | $121,907,911 | |
| 3 | INCY |
Incyte Corp
|
693,665 | $65,287,749 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
195,277 | $64,611,300 | |
| 5 | INSM |
INSMED Inc
|
272,615 | $44,578,004 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
164,542 | $31,106,665 | |
| 7 | EXEL |
Exelixis, Inc.
|
723,931 | $31,049,400 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
1,113,266 | $30,837,468 |
All Filings in ENTA
Export CSV
25 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $396,619 | 31,403 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $454,948 | 28,849 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $369,980 | 30,909 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $244,248 | 32,308 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $171,892 | 31,140 | Shares | Sole | 2025-05-29 | |
| 2024-12-31 | $213,273 | 37,091 | Shares | Sole | 2025-05-29 | |
| 2024-09-30 | $374,669 | 36,165 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $448,321 | 34,566 | Shares | Sole | 2024-08-01 | |
| 2024-03-31 | $576,494 | 33,018 | Shares | Sole | 2024-05-09 | |
| 2023-12-31 | $304,074 | 32,314 | Shares | Sole | 2024-02-08 | |
| 2023-09-30 | $362,801 | 32,480 | Shares | Sole | 2023-11-09 | |
| 2023-06-30 | $1,385,521 | 64,744 | Shares | Sole | 2023-08-08 | |
| 2023-03-31 | $2,582,579 | 63,862 | Shares | Sole | 2023-05-11 | |
| 2022-12-31 | $2,794,130 | 60,063 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $3,112,355 | 60,003 | Shares | Sole | 2022-11-10 | |
| 2022-06-30 | $2,636,720 | 55,780 | Shares | Sole | 2022-08-11 | |
| 2022-03-31 | $3,824,145 | 53,725 | Shares | Sole | 2022-05-12 | |
| 2021-12-31 | $4,048,290 | 54,136 | Shares | Sole | 2022-02-10 | |
| 2021-09-30 | $3,133,639 | 55,160 | Shares | Sole | 2021-11-12 | |
| 2021-06-30 | $2,726,683 | 61,956 | Shares | Sole | 2021-08-05 | |
| 2021-03-31 | $3,256,057 | 66,019 | Shares | Sole | 2021-05-06 | |
| 2020-12-31 | $2,747,319 | 65,257 | Shares | Sole | 2021-02-10 | |
| 2020-09-30 | $2,726,611 | 59,559 | Shares | Sole | 2020-11-12 | |
| 2020-06-30 | $3,095,095 | 61,643 | Shares | Sole | 2020-08-13 | |
| 2020-03-31 | $2,979,288 | 57,929 | Shares | Sole | 2020-05-06 | |
| No filing history on record for this holder in this stock. | ||||||